Shotlee LogoShotlee
Blog
Download on theApp Store
Get it onGoogle Play
Skip to main content
Tom Brady's GLP-1 Role: Chief Wellness Officer at eMed - Featured image
GLP-1 Medications

Tom Brady's GLP-1 Role: Chief Wellness Officer at eMed

Dr. Adrian Vale, MD
Reviewed by Dr. Adrian Vale, MDInternal Medicine · Board-Certified Obesity Medicine
·2 min read

On this page

  • Tom Brady's Pivot to Business Leadership
  • Entry into GLP-1 Medications
  • Sports Team Ownership Stakes
  • Fashion and Wellness Brands
  • Broadcasting and Media Ventures
  • Other Investments and Endorsements

Track Smart

Calculate active GLP-1 levels automatically with Shotlee.

Download →

Retired NFL star Tom Brady has taken on the role of Chief Wellness Officer at eMed, a digital health company specializing in GLP-1 medications such as Wegovy and Zepbound. These popular weight-loss drugs offer game-changing results when paired with clinical guidance. Brady's move highlights the growing intersection of sports fame and evidence-based weight management.

Share

On this page

  • Tom Brady's Pivot to Business Leadership
  • Entry into GLP-1 Medications
  • Sports Team Ownership Stakes
  • Fashion and Wellness Brands
  • Broadcasting and Media Ventures
  • Other Investments and Endorsements

Tom Brady's Pivot to Business Leadership

Tom Brady, one of the NFL's greatest quarterbacks with seven Super Bowl wins and five MVP awards, has channeled his competitive drive into business. After retiring, he invests in dozens of companies across sports, wellness, and more. His net worth stands at an estimated $530 million, per Forbes.

Entry into GLP-1 Medications

Brady recently became Chief Wellness Officer at eMed Population Health, a digital health firm specializing in GLP-1 medications. These drugs, including Wegovy (semaglutide) for weight loss and Zepbound (tirzepatide) for diabetes and obesity, have surged in popularity.

Brady emphasizes eMed's mission to improve population health through scalable GLP-1 care for workforces. "These are game-changing drugs if paired with clinical guidance," he stated. For users, tools like apps that track GLP-1 doses—such as Shotlee—support adherence and monitoring.

Sports Team Ownership Stakes

Brady maintains strong ties to sports with minority ownership in Las Vegas teams. He owns stakes in the NFL's Las Vegas Raiders (5%) and WNBA's Las Vegas Aces.

  • Raiders deal finalized in 2023; amount undisclosed.
  • Aces investment followed a 2022 game, impressed by women's basketball growth, per owner Mark Davis.

He also founded the Las Vegas Night Owls pickleball team in 2022, capitalizing on America's fastest-growing sport, according to a 2025 Sports & Fitness Industry study. In 2023, Brady acquired a 3.3% stake in English soccer club Birmingham City.

"I've got a lot to learn... but I do know a few things about winning," Brady told ESPN.

Fashion and Wellness Brands

Brady's sportswear brand, Brady Brand Clothing, launched in 2022 and merged with NOBULL in 2024, making him a major shareholder. Under NOBULL is TB12, his 2013 co-founded wellness brand offering plant-based protein powders and electrolyte supplements.

Precision tracking for your journey

Join thousands using Shotlee to accurately track GLP-1 medications and side effects.

📱 Get the Shotlee App

Track your GLP-1 medications, peptides, and health metrics on the go with our mobile app!

Download on theApp Store
Get it onGoogle Play

This aligns with the $1.8 trillion U.S. wellness industry, where GLP-1 medications play a key role in weight management.

Broadcasting and Media Ventures

In 2022, Brady signed a 10-year, $375 million Fox Sports deal—the largest in sportscasting history. He un-retired briefly but now analyzes games with Kevin Burkhardt, under restrictions due to Raiders ownership.

His 199 Productions develops sports content, including Emmy-winning "Man in the Arena" and Netflix's "The Greatest Roast of All Time: Tom Brady."

Other Investments and Endorsements

Brady co-founded NFT platform Autograph in 2021, which pivoted post-market crash and merged with Future in 2025. He holds a 50% stake in sports card retailer CardVault by Tom Brady.

Endorsements include Hertz for electric and used cars, with Executive VP Jeff Adams praising his MVP status in the used car market.

Source Information

Originally published by The Independent.Read the original article →

Read next

Keep exploring

More on Wegovy

Articles covering Wegovy dosing, side effects, and clinical updates.

Ozempic Price Cut: Generic Semaglutide Arrives in Canadian Pharmacies
Health & Wellness

Ozempic Price Cut: Generic Semaglutide Arrives in Canadian Pharmacies

Two generic versions of Ozempic have arrived in Canadian pharmacies, offering diabetes and weight loss patients significant cost savings compared to the brand-name medication.

7 min read
Retatrutide Breaks Records: What Phase 3 TRIUMPH-1 Data Means
Health & Wellness

Retatrutide Breaks Records: What Phase 3 TRIUMPH-1 Data Means

Eli Lilly's Retatrutide has shown remarkable weight loss potential in Phase 3 trials. We break down the TRIUMPH-1 results, safety data, and what patients can expect.

9 min read
GLP-1s, Hormones, and Weight Loss: What Women Need to Know
Health & Wellness

GLP-1s, Hormones, and Weight Loss: What Women Need to Know

Many women starting GLP-1 therapies experience significant weight loss, only to find their menopausal symptoms—like hot flashes and sleep issues—intensify. This phenomenon is often overlooked because rapid fat loss directly interacts with the body's declining estrogen production, creating a complex hormonal shift that many prescribers are not trained to address.

6 min read

Same topic: GLP-1

All GLP-1 articles →
New Obesity Pills in the UAE: Navigating Insurance Coverage for Wegovy and Foundayo
Metabolic Health

New Obesity Pills in the UAE: Navigating Insurance Coverage for Wegovy and Foundayo

As new weight-loss medications enter the UAE market, patients are questioning insurance coverage. We break down the realities of policy, medical necessity, and the future of metabolic health.

2 min read
Medicare Expands GLP-1 Coverage: What the 2027 Policy Shift Means for Seniors
Healthcare Policy

Medicare Expands GLP-1 Coverage: What the 2027 Policy Shift Means for Seniors

The federal government has extended its commitment to fund GLP-1 obesity medications through 2027, shifting away from private insurer mandates to protect seniors from premium hikes.

2 min read
Tirzepatide vs. Semaglutide: A Comprehensive Guide to Cost and Health Outcomes
Medical Research

Tirzepatide vs. Semaglutide: A Comprehensive Guide to Cost and Health Outcomes

A new lifetime economic analysis suggests tirzepatide may offer superior long-term value and clinical outcomes compared to semaglutide for obesity management.

2 min read

More in GLP-1 Medications

GLP-1 Weight Loss Drugs: Usage Trends and What You Need to Know
Health & Wellness

GLP-1 Weight Loss Drugs: Usage Trends and What You Need to Know

The popularity of GLP-1 receptor agonists for weight management is soaring. This article delves into the latest trends, the science behind these medications, and essential considerations for patients and healthcare providers.

7 min read
Retatrutide: Eli Lilly's New Drug Challenges Ozempic in Weight Loss
Health & Wellness

Retatrutide: Eli Lilly's New Drug Challenges Ozempic in Weight Loss

Eli Lilly's experimental drug Retatrutide is making waves with unprecedented weight loss results in clinical trials, potentially setting a new benchmark in obesity treatment. This comprehensive look examines its efficacy, mechanism, and comparison to existing GLP-1 and GIP agonists.

8 min read
GLP-1 Drugs: Understanding the Weight Loss Revolution
Health & Wellness

GLP-1 Drugs: Understanding the Weight Loss Revolution

The advent of GLP-1 receptor agonists has transformed the landscape of weight management, offering new hope for individuals struggling with obesity. This article delves into the science, benefits, potential drawbacks, and the leading players in this groundbreaking field.

7 min read
Share this article
  1. Home
  2. Blog
  3. Tom Brady's GLP-1 Role: Chief Wellness Officer at eMed
Dr. Adrian Vale, MD — Internal Medicine · Board-Certified Obesity Medicine
Medically reviewed

Dr. Adrian Vale, MD

Internal Medicine · Board-Certified Obesity Medicine

Dr. Adrian Vale is a board-certified internal medicine physician with a clinical focus on obesity medicine and metabolic health. He reviews Shotlee guides and articles on GLP-1 medications, peptide therapy, and weight-management protocols for clinical accuracy.

View all articles reviewed by Dr. Adrian Vale, MD
Shotlee LogoShotlee

Your comprehensive health tracking companion. Track, analyze, and optimize your journey with advanced metrics and community support.

Product

  • Medication Trackers
  • Health Guides
  • Calculators
  • Compare Medications
  • Pricing

Resources

  • Health Blog
  • Support Center

Legal

  • Privacy Policy
  • Terms of Service
  • Community Guidelines
  • Refund Policy

© 2026 Shotlee. All rights reserved.

Made with for the community♥ for the community